Leerink Partnrs Forecasts Exact Sciences Q4 Earnings

Exact Sciences Co. (NASDAQ:EXAS) – Research analysts at Leerink Partnrs lifted their Q4 2025 EPS estimates for Exact Sciences in a research note issued on Friday, May 2nd. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will post earnings of $0.26 per share for the quarter, up from their previous forecast of $0.18. The consensus estimate for Exact Sciences’ current full-year earnings is ($0.58) per share.

Exact Sciences (NASDAQ:EXAS) last released its quarterly earnings data on Thursday, May 1st. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.16. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. The business had revenue of $706.79 million during the quarter, compared to analysts’ expectations of $688.58 million. During the same period in the prior year, the company earned ($0.60) EPS. The firm’s quarterly revenue was up 10.9% compared to the same quarter last year.

A number of other equities analysts have also commented on EXAS. Royal Bank of Canada lifted their price objective on Exact Sciences from $52.00 to $54.00 and gave the stock a “sector perform” rating in a research note on Friday. Robert W. Baird increased their price target on Exact Sciences from $69.00 to $72.00 and gave the stock an “outperform” rating in a report on Friday. Evercore ISI boosted their target price on shares of Exact Sciences from $60.00 to $66.00 and gave the stock an “outperform” rating in a research report on Friday. Mizuho started coverage on Exact Sciences in a research note on Thursday, April 10th. They set an “outperform” rating and a $60.00 price objective on the stock. Finally, William Blair reaffirmed an “outperform” rating on shares of Exact Sciences in a research report on Thursday, February 20th. Two research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $70.90.

Exact Sciences Stock Up 9.3 %

Shares of NASDAQ EXAS opened at $51.55 on Monday. The firm has a market cap of $9.72 billion, a PE ratio of -9.25 and a beta of 0.92. The company has a 50 day simple moving average of $45.02 and a 200 day simple moving average of $53.20. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.15 and a quick ratio of 1.93. Exact Sciences has a 1 year low of $39.97 and a 1 year high of $72.83.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in EXAS. Larson Financial Group LLC increased its holdings in shares of Exact Sciences by 2,804.8% in the first quarter. Larson Financial Group LLC now owns 610 shares of the medical research company’s stock worth $26,000 after purchasing an additional 589 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Exact Sciences in the first quarter worth approximately $34,000. Asset Planning Inc bought a new position in shares of Exact Sciences during the 4th quarter valued at $40,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Exact Sciences during the fourth quarter valued at about $45,000. Finally, AlphaQuest LLC increased its stake in Exact Sciences by 22,825.0% in the 4th quarter. AlphaQuest LLC now owns 917 shares of the medical research company’s stock worth $52,000 after purchasing an additional 913 shares during the period. Hedge funds and other institutional investors own 88.82% of the company’s stock.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.